Eplerenone
Modify Date: 2026-07-12 18:24:41
Eplerenone structure
|
Common Name | Eplerenone | ||
|---|---|---|---|---|
| CAS Number | 107724-20-9 | Molecular Weight | 414.491 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 597.9±50.0 °C at 760 mmHg | |
| Molecular Formula | C24H30O6 | Melting Point | 241-243ºC | |
| MSDS | USA | Flash Point | 259.5±30.2 °C | |
Use of EplerenoneEplerenone is an aldosterone antagonist with an IC50 of 0.36 μM.Target: Mineralocorticoid ReceptorEplerenone is a selective mineralocorticoid receptor antagonist, which has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors [1]. Benefits of eplerenone therapy over placebo were also observed in several secondary outcomes, including: death from any cause or hospitalization for HF; death from any cause; hospitalization for any reason; or hospitalization for HF [2]. |
| Name | eplerenone |
|---|---|
| Synonym | More Synonyms |
| Description | Eplerenone is an aldosterone antagonist with an IC50 of 0.36 μM.Target: Mineralocorticoid ReceptorEplerenone is a selective mineralocorticoid receptor antagonist, which has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors [1]. Benefits of eplerenone therapy over placebo were also observed in several secondary outcomes, including: death from any cause or hospitalization for HF; death from any cause; hospitalization for any reason; or hospitalization for HF [2]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 597.9±50.0 °C at 760 mmHg |
| Melting Point | 241-243ºC |
| Molecular Formula | C24H30O6 |
| Molecular Weight | 414.491 |
| Flash Point | 259.5±30.2 °C |
| Exact Mass | 414.204254 |
| PSA | 82.20000 |
| LogP | 1.05 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.587 |
| InChIKey | JUKPWJGBANNWMW-AORFUQRWSA-N |
| SMILES | COC(=O)C1CC2=CC(=O)CCC2(C)C23OC2CC2(C)C(CCC24CCC(=O)O4)C13 |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | 3077 |
| HS Code | 29322090 |
CAS#:95716-70-4
CAS#:67-56-1![4'S(4'α),7'α-hexadecahydro-11'α-hydroxy-10'β,13'beta-dimethyl-3',5,20'-trioxospiro[furan-2(3H),17'β-[4,7]metheno(17H)cyclopenta[a]phenanthrene]-5'β(2'H)-carbonitrile Structure](https://image.chemsrc.com/caspic/278/192704-54-4.png)
CAS#:192704-54-4
CAS#:124-41-4
CAS#:192569-17-8
CAS#:95716-71-5|
Lung fibrosis: drug screening and disease biomarker identification with a lung slice culture model and subtracted cDNA Library.
Altern. Lab. Anim. 42(4) , 235-43, (2014) Pulmonary fibrosis is a progressive and irreversible disorder with no appropriate cure. A practical and effective experimental model that recapitulates the disease will greatly benefit the research co... |
|
|
Depressor effect of chymase inhibitor in mice with high salt-induced moderate hypertension.
Am. J. Physiol. Heart Circ. Physiol. 309 , H1987-96, (2015) The aim of the present study was to determine whether long-term high salt intake in the drinking water induces hypertension in wild-type (WT) mice and whether a chymase inhibitor or other antihyperten... |
|
|
The Other Side of the RAAS: Aldosterone Improves Migration of Cardiac Progenitor Cells.
J. Cell Physiol. 230 , 2829-36, (2015) Stem cell therapy is a promising new option for patients suffering from heart failure. Though many clinical studies show encouraging results, little is known about the signals which cause stem cells t... |
Total 518, Current Page 1 of 52
1
2
3
4
5
| Methyl (4aS,4bR,5aR,6aS,7R,9aS,9bR)-4a,6a-dimethyl-2,5'-dioxo-2,4,4',4a,5',5a,6,6a,8,9,9a,9b,10,11-tetradecahydro-3H,3'H-spiro[cyclopenta[7,8]phenanthro[4b,5-b]oxirene-7,2'-furan]-10-carboxylate |
| (4aS,4bR,5aR,6aS,7R,9aS,9bR,10R)-4a,6a-diméthyl-2,5'-dioxo-2,4,4',4a,5',5a,6,6a,8,9,9a,9b,10,11-tétradécahydro-3H,3'H-spiro[cyclopenta[7,8]phénanthro[4b,5-b]oxirène-7,2'-furane]-10-carboxylate de méthyle |
| Methyl-(4aS,4bR,5aR,6aS,7R,9aS,9bR,10R)-4a,6a-dimethyl-2,5'-dioxo-2,4,4',4a,5',5a,6,6a,8,9,9a,9b,10,11-tetradecahydro-3H,3'H-spiro[cyclopenta[7,8]phenanthro[4b,5-b]oxiren-7,2'-furan]-10-carboxylat |
| Inspra |
| EplerenoneC24H3006 |
| 9,11a-Epoxy-17-hydroxy-3-oxo-17a-pregn-4-ene-7a,21-dicarboxylic Acid g-Lactone Methyl Ester |
| Methyl (4aS,4bR,5aR,6aS,7R,9aS,9bR,10R)-4a,6a-dimethyl-2,5'-dioxo-2,4,4',4a,5',5a,6,6a,8,9,9a,9b,10,11-tetradecahydro-3H,3'H-spiro[cyclopenta[7,8]phenanthro[4b,5-b]oxirene-7,2'-furan]-10-carboxylate |
| Elperenone |
| Epleremone |
| epoxymexrenone |
| Eplerenone |
| spiro[cyclopenta[7,8]phenanthro[4b,5-b]oxirene-7(3H),2'(3'H)-furan]-10-carboxylic acid, 2,4,4',4a,5',5a,6,6a,8,9,9a,9b,10,11-tetradecahydro-4a,6a-dimethyl-2,5'-dioxo-, methyl ester, (4aS,4bR,5aR,6aS,7 |
| Methyl (4aS,4bR,5aR,7R,9aS,9bR,10R)-4a,6a-dimethyl-2,5'-dioxo-2,4,4',4a,5',5a,6,6a,8,9,9a,9b,10,11-tetradecahydro-3H,3'H-spiro[cyclopenta[7,8]phenanthro[4b,5-b]oxirene-7,2'-furan]-10-carboxylate |
| 9,11α-Epoxy-17-hydroxy-3-oxo-17α-pregn-4-ene-7α,21-dicarboxylic Acid γ-Lactone Methyl Ester |
| EPLERINONE |